AMPKα2 Regulates Hypoxia-Inducible Factor-1α Stability and Neutrophil Survival to Promote Vascular Repair After Ischemia

Kimio Satoh

Circulating cytokines/chemokines and growth factors regulate endothelial function and influence the development of cardiovascular diseases. Cardiovascular diseases are characterized by endothelial dysfunction, vascular smooth muscle cell (VSMC) proliferation, and inflammatory cell migration, leading to obliteration or excessive enlargement of vascular lumens. Endothelial dysfunction is induced by cardiovascular risk factors, including hypertension, diabetes mellitus, dyslipidemia, and smoking, all of which trigger a variety of vascular disorders. Recently, AMP-activated protein kinase (AMPK) has been demonstrated as an important regulator of metabolic functions, including the regulation of cellular energy homeostasis and metabolism. AMPK is an evolutionarily conserved serine/threonine kinase that functions as an important energy sensor and plays a crucial role in vascular homeostasis. Moreover, AMPK is a master regulator that senses cellular energetics in part through the AMP/ATP ratio and mitochondrial reactive oxygen species production and coordinates cell-autonomous responses to metabolic stress. Importantly, AMPK has an antiapoptotic effect in endothelial cells and a proapoptotic effect in VSMCs, which are critical for vascular remodeling. The interactions between endothelial cells, VSMCs, adventitial cells, and inflammatory cells play crucial roles in the development of vascular diseases. Both endothelial nitric oxide (NO) production and NO-mediated signaling in endothelial cells and VSMCs are targets and effectors of the AMPK signaling pathway. Furthermore, AMPK regulates many other stimuli modulating vascular functions, including reactive oxygen species, that promote VSMC proliferation by auto/paracrine growth mechanisms. AMPK is a heterotrimeric complex consisting of a catalytic subunit (α) and 2 regulatory subunits (β and γ), each having ≥2 isoforms (α1, α2, β1, β2, γ1, γ2, and γ3) that are differentially expressed in various tissues and subcellular locations. In the vascular endothelium, both α-subunits of AMPK are expressed, although AMPK-α1 is expressed to a greater extent than AMPK-α2. Endothelium-dependent vasodilatation is a vital mechanism of blood flow regulation in response to increased metabolic demand (Figure). We have demonstrated that endothelial AMPK plays an important role in microvascular homeostasis and regulation of systemic arterial pressure in mice in vivo. As a metabolic sensor, endothelial AMPK plays an important role in the metabolic regulation of blood flow, which is regulated by endothelial NO synthase through the activation of the AMPK-α1 subunit (Figure). Endothelial-specific AMPK-knockout mice and the resultant endothelial dysfunction induce increased expression of inflammatory cell adhesion molecules. Accumulated inflammatory cells generate an oxidizing environment, which involves abundant reactive oxygen species, inflammatory cytokines/chemokines, and growth factors that contribute to aortic aneurysm formation, which is also regulated by AMPK-α2 in VSMCs. Oxidative stress and a shift in the cellular redox balance have been linked with endothelial dysfunction at the early stages of cardiovascular diseases. In contrast, AMPK can inhibit reactive oxygen species formation through NADPH oxidase and stimulate NO production by endothelial NO synthase. Indeed, AMPK has been suggested to phosphorylate the p47phox subunit and thus prevent its translocation to the plasma membrane.

Arteriogenesis and angiogenesis are determined by endothelial cells and by circulating inflammatory cells.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Correspondence to Kimio Satoh, MD, PhD, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. E-mail satoh-k@cardio.med.tohoku.ac.jp

Circ Res. 2017;120:8-10.
DOI: 10.1161/CIRCRESAHA.116.310217.
© 2017 American Heart Association, Inc.

Circulation Research is available at http://circres.ahajournals.org
DOI: 10.1161/CIRCRESAHA.116.310217

Article, see p 99
the authors used in vitro and ex vivo approaches and showed that AMPK-α2 is linked to an increase in early neutrophil infiltration, the upregulation of inflammatory cytokines, and adhesion molecule expression. Finally, the authors precisely demonstrated the molecular mechanism by which the AMPK-α2 in neutrophils is required for protection against apoptosis under hypoxic conditions via regulating hypoxia-inducible factor-1α (HIF-1α). The phosphorylation and activation of AMPK-α2 by hypoxia leads to decreased IDH expression and decreased levels of α-KG. Stabilized HIF-1α translocates to the nucleus and forms an active HIF complex that induces the expression of proangiogenic genes that support survival and decrease mitochondrial respiration. PGH indicates prostaglandin H; PLC, phospholipase C; PVL, von-Hippel-Lindau protein; SOD, superoxide dismutase; and VEGF, vascular endothelial growth factor.

Clinical Significance

Several drugs and molecules activate AMPK, all of which could be potentially protective against the development of vascular diseases. AMPK activation by statins and metformin has been proposed to contribute to the pleiotropic effects of this compound class. In addition, pharmacological interventions that include aspirin, 5-aminomimidazole-4-carboxamide riboside, thiazolidinediones, and the phytochemicals berberine, quercetin, and resveratrol have the ability to activate AMPK signaling by raising the (AMP+ADP)/ATP ratio as a consequence of mitochondrial electron transport and glycolysis inhibition. In this study, the authors have shown that AMPK-α2 activation in neutrophils is a decisive event in the initiation of vascular repair after ischemia. These findings may have great therapeutic impact, leading to the development of novel therapeutic strategies using AMPK activators against cardiovascular diseases. Indeed, AMPK activation by oral administration of metformin has been shown to inhibit pulmonary VSMC proliferation and ameliorate the development of pulmonary hypertension. The pathobiology of cardiovascular diseases includes endothelial dysfunction,
VSMC proliferation, and inflammatory cell migration. Thus, AMPK may represent a novel therapeutic target against endothelial dysfunction, VSMC proliferation, inflammation, and vascular repair after ischemia. The present findings also suggest that AMPK activation may represent a novel strategy to target vascular repair and angiogenesis in response to hypoxia. Thus, we expect that a highly selective, tissue-specific AMPK activator will be developed in the near future.

Sources of Funding

This work was supported in part by the grants-in-aid for Scientific Research (15H02535, 15H04816, and 15K15046), all of which are from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan; the grants-in-aid for Scientific Research from the Ministry of Health, Labour, and Welfare, Tokyo, Japan (10102895); and the grants-in-aid for Scientific Research from the Japan Agency for Medical Research and Development, Tokyo, Japan (15ak0101035h0001 and 16ek0109176h0001).

Disclosures

None.

References


Key Words: Editorials ■ apoptosis ■ chemokines ■ cytokines ■ hypertension ■ neutrophils
AMPKα2 Regulates Hypoxia-Inducible Factor-1α Stability and Neutrophil Survival to Promote Vascular Repair After Ischemia
Kimio Satoh

*Circ Res.* 2017;120:8-10
doi: 10.1161/CIRCRESAHA.116.310217

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/120/1/8

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation Research* is online at:
http://circres.ahajournals.org//subscriptions/